MX2010009739A - Inhibidores de cinasa pim y metodos para su uso. - Google Patents

Inhibidores de cinasa pim y metodos para su uso.

Info

Publication number
MX2010009739A
MX2010009739A MX2010009739A MX2010009739A MX2010009739A MX 2010009739 A MX2010009739 A MX 2010009739A MX 2010009739 A MX2010009739 A MX 2010009739A MX 2010009739 A MX2010009739 A MX 2010009739A MX 2010009739 A MX2010009739 A MX 2010009739A
Authority
MX
Mexico
Prior art keywords
methods
new compounds
kinase inhibitors
pim kinase
pharmaceutically acceptable
Prior art date
Application number
MX2010009739A
Other languages
English (en)
Inventor
Matthew Burger
Mika Lindvall
Gisele Nishiguchi
Jiong Lan
Michelle Tetalman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009739(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010009739A publication Critical patent/MX2010009739A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de las fórmulas I y II, a sus tautómeros, estereoisómeros y polimorfos, y a las sales farmacéuticamente aceptables, ésteres, metabolitos o pro-fármacos de los mismos, a composiciones de los nuevos compuestos junto con vehículos farmacéuticamente aceptables, y al uso de los nuevos compuestos, ya sea solos o bien en combinación con cuando menos un agente terapéutico adicional, en la inhibición de la actividad de la cinasa Pim y/o en la profilaxis o el tratamiento de cáncer. (ver fórmulas).
MX2010009739A 2008-03-03 2009-03-03 Inhibidores de cinasa pim y metodos para su uso. MX2010009739A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3335908P 2008-03-03 2008-03-03
PCT/EP2009/052506 WO2009109576A1 (en) 2008-03-03 2009-03-03 Pim kinase inhibitors and methods of their use

Publications (1)

Publication Number Publication Date
MX2010009739A true MX2010009739A (es) 2010-09-28

Family

ID=41055566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009739A MX2010009739A (es) 2008-03-03 2009-03-03 Inhibidores de cinasa pim y metodos para su uso.

Country Status (21)

Country Link
EP (2) EP2262802B1 (es)
JP (1) JP5412448B2 (es)
KR (1) KR20100120709A (es)
CN (2) CN102015701B (es)
AR (1) AR070531A1 (es)
AU (1) AU2009221134B2 (es)
BR (1) BRPI0909102A2 (es)
CA (1) CA2717388A1 (es)
CL (1) CL2009000483A1 (es)
CO (1) CO6290687A2 (es)
EA (1) EA201001412A1 (es)
EC (1) ECSP10010447A (es)
ES (2) ES2443496T3 (es)
IL (1) IL207865A0 (es)
MA (1) MA32135B1 (es)
MX (1) MX2010009739A (es)
PE (1) PE20091577A1 (es)
TW (1) TW200942536A (es)
UY (1) UY31679A1 (es)
WO (1) WO2009109576A1 (es)
ZA (1) ZA201006128B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214483B (zh) 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
RS54506B1 (en) * 2008-09-02 2016-06-30 Novartis Ag PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5567136B2 (ja) * 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
KR102283091B1 (ko) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
SG184475A1 (en) 2010-04-07 2012-11-29 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9156827B2 (en) 2010-04-30 2015-10-13 The University Of Tokyo Anticancer agent
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
US20120225061A1 (en) * 2011-03-04 2012-09-06 Matthew Burger Tetrasubstituted cyclohexyl compounds as kinase inhibitors
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
CN102924445B (zh) * 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG2014012579A (en) 2011-09-27 2014-04-28 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
KR20150013548A (ko) * 2012-05-21 2015-02-05 노파르티스 아게 키나제 억제제로서의 신규 고리-치환된 n-피리디닐 아미드
WO2014033630A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
WO2014033631A1 (en) * 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
CN104640858B (zh) 2012-09-26 2018-11-06 霍夫曼-拉罗奇有限公司 环醚吡唑-4-基-杂环基-甲酰胺化合物及使用方法
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
MX2015009057A (es) * 2013-01-15 2015-10-05 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de cinasa pim.
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
EP3030227B1 (en) 2013-08-07 2020-04-08 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019057821A1 (en) * 2017-09-20 2019-03-28 Lead Discovery Center Gmbh COUMARIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND USES THEREOF IN THE TREATMENT OF CANCER
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PE20211310A1 (es) 2018-01-30 2021-07-22 Incyte Corp Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento
JP2021519775A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
US20210113562A1 (en) 2018-04-13 2021-04-22 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028467A1 (en) 2003-09-15 2005-03-31 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US20090209522A1 (en) * 2005-06-28 2009-08-20 Graham Andrew Showell Heterocyclic Non-Peptide GNRH Antagonists
AR056785A1 (es) * 2005-11-10 2007-10-24 Schering Corp COMPUESTOS DE IMIDAZO[1,2-A]PIRAZINAS, uTILES COMO INHIBIDORES, REGULADORES O MODULADORES DE PROTEINQUINASAS
MX2008013400A (es) * 2006-04-19 2008-11-10 Astellas Pharma Inc Derivado de azolcarboxamida.
EP2078003B1 (en) 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
US8318735B2 (en) 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
WO2008054701A1 (en) * 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
JP5330274B2 (ja) * 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法

Also Published As

Publication number Publication date
MA32135B1 (fr) 2011-03-01
IL207865A0 (en) 2010-12-30
BRPI0909102A2 (pt) 2019-01-15
CN102015701A (zh) 2011-04-13
EP2262802A1 (en) 2010-12-22
AR070531A1 (es) 2010-04-14
ES2443496T3 (es) 2014-02-19
JP2011513363A (ja) 2011-04-28
WO2009109576A1 (en) 2009-09-11
UY31679A1 (es) 2009-09-30
JP5412448B2 (ja) 2014-02-12
EA201001412A1 (ru) 2011-06-30
ES2562306T3 (es) 2016-03-03
CN102015701B (zh) 2014-07-23
CL2009000483A1 (es) 2010-02-19
ECSP10010447A (es) 2010-10-30
CA2717388A1 (en) 2009-09-11
ZA201006128B (en) 2011-10-26
EP2262802B1 (en) 2013-10-23
EP2596790B1 (en) 2015-12-09
AU2009221134B2 (en) 2012-02-23
EP2596790A1 (en) 2013-05-29
AU2009221134A1 (en) 2009-09-11
TW200942536A (en) 2009-10-16
KR20100120709A (ko) 2010-11-16
CO6290687A2 (es) 2011-06-20
PE20091577A1 (es) 2009-11-05
CN104098559A (zh) 2014-10-15

Similar Documents

Publication Publication Date Title
MX2010009739A (es) Inhibidores de cinasa pim y metodos para su uso.
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
MX2014002683A (es) Derivados de benzonitrilo como inhibidores de cinasa.
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
UA97821C2 (en) Cyclized derivatives as eg-5 inhibitors
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
MX2009005071A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
IL219643A0 (en) Kinase inhibitors and methods of use thereof
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
TN2010000402A1 (en) Pim kinase inhibitors and methods of their use
TR201901937T4 (tr) 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri.
MY187891A (en) Tetrahydropyridine derivatives as fabi inhibitors
NZ620928A (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal